You are here:

lamivudine / zidovudine (Combivir)

Advice

Following an abbreviated submission

lamivudine/zidovudine fixed dose combination (Combivir) in antiretroviral combination therapy is accepted for use within NHS Scotland for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) in paediatric patients weighing 14kg to 30kg.

This combination is listed in the British National Formulary for Children for the treatment of HIV infection. It was previously licensed for use in adults and adolescents weighing at least 30kg. The availability of both the combination product and its active ingredients pre-date the establishment of the Scottish Medicines Consortium.

Drug Details

Drug Name: lamivudine / zidovudine (Combivir)
SMC Drug ID: 569/09
Manufacturer: GlaxoSmithKline UK Ltd
Indication: HIV infection (paediatric patients).
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 7 September 2009

Back